GlassScriptPhysician profile
Anthony J Katz
NPI 1104865922
$9,686.73
in general payments reported to CMS, 2019-2025
64 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $316 · 2021: $801 · 2022: $1,241 · 2023: $1,896 · 2024: $2,351 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,517.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,122.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $867.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $773.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.65 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $438.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.98 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $363.15 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $337.91 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $319.57 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $292.33 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Allergan, INC. | $253.09 | 2019-2020 | |
| Glaxosmithkline, LLC. | $251.39 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $189.57 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $169.07 | 2019-2025 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $148.19 | 2023-2024 | Rexulti |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.